Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

The Growing Link Between Cancer and Alzheimer’s Disease

August 1, 2019
By Christina Bennett, MS
Article

People with cancer had a slower rate of memory decline both before and after diagnosis, compared with people who were cancer-free, according to the results of a population-based cohort study recently reported in JAMA Network Open. Previous research has shown an inverse association between developing cancer and Alzheimer’s disease, and this study provides further support for this relationship.

The study cohort was made up of 14,583 adults from the Health and Retirement Study who were born before 1949 and had no diagnosis of cancer by 1998. Participants were followed from 1998 to 2014, and during those 16 years, a total of 12,333 participants remained cancer-free and 2,250 developed cancer.

A survey was conducted in 1998 to set a baseline; during the follow-up period, telephone or in-person biennial interviews were conducted to gather additional information, such as whether a participant had been diagnosed with cancer. Proxy interviews were permitted for adults who were too impaired to answer by themselves.

Memory function was assessed throughout follow-up. To assess memory function, participants were asked to recall a 10-word list both immediately and after a delayed period of time. For participants who were too impaired, a proxy was asked to evaluate the individual’s memory according to a 5-item Likert scale and complete the 16-item Informant Questionnaire for Cognitive Decline.

“This is a very important contribution to the literature,” Jane Driver, MD, Division of Aging, Brigham and Women’s Hospital, told Cancer Network.  “[The study] provides a level of evidence that’s stronger than a lot of prior studies, which were really only able to look at overall associations using diagnoses. Here, we actually have a diagnostic test that’s actually measuring cognition and its change over time.”

The study revealed that before a cancer diagnosis was made, participants had a 10.5% (95% CI, 6.2%–14.9%) slower rate of memory decline compared with participants who remained cancer free. After a new cancer diagnosis, the memory appeared to decline but this effect was transient. After a cancer diagnosis, cancer survivors had a 3.9% (95% CI, 0.9%–6.9%) slower rate of memory decline compared with cancer-free individuals. 

Driver said this is a population-based study and the authors were able to look at large numbers of patients, which is “really necessary” to try to answer the question of whether cancer and Alzheimer’s disease were inversely related. In addition, she applauded the study authors’ use of cognitive assessments over time.

“Both before and after the cancer diagnosis, overall, people who develop cancer seem to develop cognitive impairment more slowly than the comparison subjects,” said Driver. “That does really suggest that there’s something to this inverse association, and that maybe it’s not all due to some kind of a bias, which many people have attributed this relationship to over the years.”
About the inclusion of proxy assessments, Driver was not particularly critical, explaining that it’s “to be expected” that as people age and their cognition gets worse, they’re going to need a proxy to provide the information.

“The take home [message] is that it’s worth pursuing the underlying biological explanations for this because although there’s many treatments for cancer, we don’t yet have one effective treatment for Alzheimer’s disease,” said Driver. “I think that many of us are hoping that further investigation of this strange association would perhaps lead us closer to a treatment for Alzheimer’s or at least understanding it better than we have so far.”

 

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Related Content
Advertisement

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 12th 2025
Article

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 12th 2025
Article

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.


Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.


We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

Related Content
Advertisement

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 12th 2025
Article

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 12th 2025
Article

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.


Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.


We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.